About Us | Contact Us |        

Optimizing Management of Patients with Chronic Myelogenous Leukemia: Therapeutic Strategies Making A Difference

Hematology-Oncology
Curriculum:
Optimizing Management of Chronic Myelogenous Leukemia: A Community-Focused, Clinical Looking Glass Initiative
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
August 01, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

hematologists/oncologists who treat or manage patients with CML, oncology nurses, oncology nurse practitioners, physician assistants, oncology pharmacists.

Relevant Terms:

Chronic Myelogenous Leukemia

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center
University of Washington

Dr. Jerald Radich is a Member of the Clinical Research Division and Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine in Seattle, WA. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, co-chair of the NCI/NIH Leukemia Steering Committee, and is on the Board of Scientific Counselors for the NIH Genome Research Institute.  He belongs to the National Comprehensive Cancer Network (NCCN) and the EuroLeukemiaNet (ELN) CML committees, and is on the Scientific Board of the International CML Foundation. Dr. Radich's laboratory work centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia.

Peer Reviewer:
Amit Verma, MD

Peer Reviewer:
Amit Verma, MD
Associate Professor, Department of Medicine (Oncology)
Associate Professor, Department of Developmental & Molecular Biology
Albert Einstein College of Medicine
Director, Division of Hematologic Malignancies
Montefiore Medical Center
Bronx, New York

Amit K. Verma, MD, is Associate Professor of Oncology and of Developmental and Molecular Biology at the Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, Bronx, New York. He is a recipient of a Young Investigator Award from the American Society of Clinical Oncology; an American Cancer Society Research Scholar Award; and a Leukemia and Lymphoma Scholar in Clinical Research Award. Dr. Verma trained at the University of Illinois, Champaign, Illinois, and previously was a member of the faculty at the University of Texas Southwestern Medical Center, Houston, Texas.
1. Apply mutational testing strategies to inform optimal treatment and monitoring of CML patients 
2. Explain and interpret molecular response criteria in CML
3. Identify and define what constitutes poor response, resistant disease, disease intolerance, and strategies to overcome these challenges
4. Apply evidence-based updates for selecting optimal treatment for first-line and second-line therapy including when to consider combination and maintenance options
5. Implement best-practice recommendations for improving patient compliance to oral therapy
6. Evaluate recent trial data on current and novel agents and incorporate newly available treatment options for patients with CML 
7. Compare and contrast the safety, tolerability, and clinical outcomes of all options now available for the treatment of patients with CML

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above



 
 
This activity is jointly provided by Albert Einstein College of Medicine of Yeshiva University and AXIS Medical Education
 
MEDIUM: CME Enduring Material Virtual Grand Rounds
 
Estimated Time To Complete This Activity: 1.0 hour
 
INTENDED AUDIENCE
This activity is intended for hematologists/oncologists who treat or manage patients with CML. A secondary audience is oncology nurses, oncology nurse practitioners, physician assistants, and oncology pharmacists.
 
STATEMENT OF NEED
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder of the hematopoietic stem cells. Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML by effectively targeting the BCR-ABL oncogenic kinase. Many questions remain regarding the use of first, second, and third generation TKI agents in the management of CML and how to best utilize these available treatments in the front and second line settings, through combination approaches and through maintenance therapy options. Further, despite their profound activity, a substantial proportion of CML patients develop intolerance to therapy or resistant disease. The optimal choice of treatment for patients with CML represents an area of uncertainty among clinicians. The advent of mutational testing and analysis has opened the gateway toward more individualized treatment and offers clinicians with insights regarding appropriate therapeutic choices for certain patients.  It is now imperative that clinicians treating CML patients understand how to utilize this information to monitor for disease response, identify optimal timing and need for switching therapies, and communicate the importance of the patient’s role in compliant treatment to maximize clinical benefit.
 
DISCLOSURE POLICY STATEMENT
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
 
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
 
The CCME staff of Albert Einstein College of Medicine of Yeshiva University has no conflicts of interest with commercial interests related directly or indirectly to this educational activity.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Jocelyn Timko, BS, Diedrea White, BA, Deborah Middleton, MS, and Timothy DiChara, PhD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
FACULTY DISCLOSURES
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Jerald P. Radich, MD reported a financial interest/relationship or affiliation in the form of: Grants/Research Funding: Novartis Pharmaceuticals Corporation
Consultant: Ariad Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation.
 
Dr. Radich has indicated that his relationships will not impact his ability to author an unbiased presentation.
 
Amit Verma, MD reported a financial interest/relationship or affiliation in the form of:
Speakers’ Bureau: Celgene
 
UNLABELED OR INVESTIGATIONAL PRODUCT DISCUSSION:
The faculty have indicated that this enduring material does not include the unlabeled/investigational use of a commercial product or device.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and AXIS Medical Education. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
FUNDING ACKNOWLEDGEMENT
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
 
DISCLAIMER
The opinions and recommendations expressed by faculty in this activity are their own and do not necessarily represent the views of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, AXIS Medical Education or RealCME.

Participants are advised to consult prescribing information for all specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
 
METHOD OF PARTICIPATION AND RECEIVING CME CREDIT
There are no fees for participating in and receiving credit for this activity. The participant must read the learning objectives, faculty disclosures and enduring material, and must answer the multiple-choice online post-test, and evaluation form which provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his/her views on future educational needs.

Upon successful completion of the post-test with a passing grade of 70%, and the evaluation, physicians will receive CME credit and all other healthcare professionals will receive a certificate of participation. A certificate will be available to print from your user history page.
 
RELEASE DATE: August 1, 2014
 
TERMINATION DATE: August 1, 2015 
 
COPYRIGHT INFORMATION
Copyright © 2014 Albert Einstein College of Medicine of Yeshiva University. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
 
PRIVACY POLICY
Albert Einstein College of Medicine, Center for Continuing Medical Education (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding Albert Einstein College of Medicine's Privacy Policy can be viewed at http://www.mecme.org/site/privacy.php

If you have questions about this CME activity, please contact Albert Einstein College of Medicine at 1-718-920-6674 or cme@montefiore.org.